When antidepressant medications aren’t working for your loved one,

TAP INTO A NEW POSSIBILITY for depression treatment

Over 22 million people in the US suffer from major depressive disorder. Unfortunately, more than 1 in 4 depression sufferers report being unhappy with the results they get from antidepressant medications.¹,²,³

But there is an alternative.

Depression Isolates. NeuroStar Connects.

NeuroStar:
• IS FDA-cleared, with over 4.5 million treatments performed to date
• IS safe and effective
• IS NOT a drug, invasive or “shock therapy”
• IS covered by most insurance: Over 300 million people have insurance plans that cover NeuroStar treatment.

What is NeuroStar TMS?
NeuroStar TMS is a proven non-drug depression treatment for people who have not been helped by antidepressants.

TMS stands for transcranial magnetic stimulation, which uses focused magnetic pulses—similar in strength to an MRI (magnetic resonance imaging)—to stimulate areas of the brain that are underactive in people with depression. Scientists believe this pattern of repetitive stimulation of the brain induces neuroplasticity—the brain’s ability to adapt and change—which contributes to the treatment’s durability.

NeuroStar focuses depression treatment at the source, delivering the right dose of treatment to the right location every time.

#1 Choice of TMS Doctors
Depression Treatment that Fits into Daily Life

NeuroStar is an easy, in-office treatment with the majority of patients experiencing significant, long-lasting improvement.

**Customized.** Treatment is based on your specific diagnosis, with sessions lasting as little as 19 minutes, 5 days a week for 36 sessions. Completing the full NeuroStar treatment course gives the best chance for delivering long-lasting relief from depression.

**Comfortable.** Patients recline comfortably in the treatment chair, and can read, talk with their treatment coordinator, or even meditate during sessions.

**Convenient.** There is no sedation or anesthesia—patients remain awake and alert during treatment, with no effect on alertness or memory, and can drive home and resume normal activities immediately afterward.

Visit NeuroStar.com today to learn more.

Rich & Elsa: Real People, Real NeuroStar Results

For years Rich hid his depression from everyone, including his wife Elsa. After several unsuccessful attempts with antidepressant medications, he finally confided in her and together they researched other options. Elsa discovered NeuroStar and thought it might be the possibility Rich needed. After an initial consultation with a NeuroStar doctor, a treatment plan was designed and within weeks Rich was happier and more confident than he had been in years.

Thanks to NeuroStar—and my wife—I am living my life to the fullest. I only wish I had discovered NeuroStar TMS sooner.

— Rich

Visit NeuroStar.com to see more real stories.

Caregiver Tips for NeuroStar Success

1. **Remember, depression is a disease.** Supporting someone with depression will have its ups and downs, and together you are working towards a better outcome.

2. **Don’t go it alone.** Do your best to stay positive and rely on your friends, family, and support system as you need.

3. **Stay in sync.** Connect with each other after each treatment session, whether for a meal, a cup of coffee, or even a phone call.

4. **Be patient.** Subtle improvements could be a sign of positive progress; be on the lookout for changes and trust in the process.

NeuroStar is only available by prescription. Results may vary. A doctor can help decide if NeuroStar is right for you. NeuroStar Advanced Therapy is indicated for the treatment of major depressive disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).

2. Per STAR*D patients that have failed one or more antidepressant trial of adequate dose and duration.